UFT plus carboplatin for head and neck cancer

Masato Fujii, Yoshihiro Ohno, Yutaka Tokumaru, Yorihisa Imanishi, Minoru Kanke, Toshiki Tomita, Taku Yamashita

研究成果: Article査読

6 被引用数 (Scopus)


Cisplatin plus fluorouracil (5-FU) is widely accepted as neoadjuvant and adjuvant chemotherapy in the treatment of head and neck squamous cell carcinoma; UFT is also an active agent against this disease. In the first retrospective study, we examined the efficacy of UFT as adjuvant chemotherapy in patients with maxillary cancer. The 5-year survival rate of those treated with UFT vs those not treated was 71.4% vs 23.8%, respectively. In the second study we developed the carboplatin plus UFT regimen - as a modification of cisplatin plus 5-FU -and studied its efficacy and toxicity in patients with advanced head and neck squamous cell carcinoma. These patients received UFT plus carboplatin. The objective response rate was 53.1%; grade ≥ 3 leukopenia, anemia, and thrombocytopenia were rare. These findings suggest that UFT plus carboplatin in the outpatient setting is feasible for patients with head and neck squamous cell carcinoma.

10 SUPPL. 9
出版ステータスPublished - 2000 12月 1

ASJC Scopus subject areas

  • 腫瘍学
  • 癌研究


「UFT plus carboplatin for head and neck cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。